advanced topics in the submission of research protocols to the institutional review board (irb) and...
TRANSCRIPT
![Page 1: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/1.jpg)
Advanced Topics in the Submission of Research Protocols to the
Institutional Review Board (IRB) and the Office for the
Protection of Human Subjects (OPHS)
Maryann Rossi, PhD, CIM, CIPAccreditation and Education Manager
OPHS
ASAP Course; November 18, 2009
IRB 201
![Page 2: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/2.jpg)
Participants will:
• Know key PI responsibilities under human subject protection regulations
• Learn how the HIPAA Privacy Rule relates to research
• Know what Data and Safety Monitoring Plans are and when to have one
Learning Objectives
![Page 3: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/3.jpg)
Learning Objectives (cont.)
• Be able to identify protocol deviations and Serious Adverse Events; know when and how to report them
• Understand concepts of waiver of informed consent/assent and waiver of documentation of informed consent/assent
• Become familiar with Emergency Use Exemption
• Be introduced to regulatory requirements for multi-site studies
![Page 4: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/4.jpg)
Organizational Plan
Education Programs
Conflict
of Interest Investigators and Research Staff
Compliance Oversight
Communications System
Institutional Review Board
Investigational Drug Services
Contracts and Grants
Office for the Protection of Human Subjects
Human Research Protection Program (HRPP) Components
![Page 5: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/5.jpg)
PI Responsibilities (1)
• To conduct research ethically and in accordance with regulations, CNMC policies, and IRB requirements
• To ensure research personnel have appropriate qualifications and required training (e.g., CITI)
• To have sufficient resources to ensure appropriate care, oversight, and safety of subjects
![Page 6: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/6.jpg)
PI Responsibilities (2)
• To obtain and document informed consent and assent in accordance with regulatory requirements unless otherwise authorized by the IRB
• To protect subject privacy and data confidentiality
• To follow the protocol as approved by IRB
![Page 7: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/7.jpg)
• To obtain IRB approval prior to implementing any protocol modifications
• To monitor the data to ensure subject safety and welfare
• To report to the IRB unanticipated, serious events or other unanticipated problems that involve risks to subjects or others
PI Responsibilities (3)
![Page 8: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/8.jpg)
• To submit Continuing Review reports on a timely basis to avoid protocol expiration
• To submit a final report to the IRB at study closure
*****
The PI bears the ultimate responsibility for his/her research staff and how the protocol is conducted.
PI Responsibilities (4)
![Page 9: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/9.jpg)
HIPAA
• Heath Insurance Portability and Accountability Act of 1996 (HIPAA)
• Protected Health Information (PHI)
• Includes individually identifiable information
• Covered Entities (CE):– Health Care Provider– Health Plan– Health Care Clearinghouse
![Page 10: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/10.jpg)
1st Belmont Ethical Principle
RESPECT FOR PERSONS• Treat individuals as autonomous
agents• Right to know• Right to choose• Right to privacy and confidentiality• Right to withdraw
• Additional protections for persons with reduced autonomy
![Page 11: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/11.jpg)
Privacy vs. Confidentiality
Privacy• Is about people• Refers to persons’ interest in controlling
access to themselves
Confidentiality• Is about data• Refers to agreements with the participant
about how data are to be handled
![Page 12: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/12.jpg)
18 HIPAA Identifiers
1. Name
2. Any geographic subdivisions smaller than a state (except initial 3 digits of ZIP code)
3. All elements of dates (except year) directly related to an individual (e.g., DOB, date of admission)
4. Telephone numbers
5. Fax numbers
6. Electronic mail addresses
![Page 13: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/13.jpg)
HIPAA Identifiers (cont.)
7. Social security numbers
8. Medical record numbers
9. Health plan beneficiary numbers
10. Account numbers
11. Certificate/license numbers
12. Vehicle identifiers and serial numbers (including license plate numbers)
13. Device identifiers and serial numbers
![Page 14: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/14.jpg)
HIPAA Identifiers (cont.)
14. Web Universal Resource Locators (URLs)
15. Internet Protocol (IP) address numbers
16. Biometric identifiers, including finger and voiceprints
17. Full-face photographic images and any comparable images
18. Any other unique identifying number, characteristic, or code
![Page 15: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/15.jpg)
Implications for Research
• Investigator must obtain patient’s permission before using PHI– Part of the standard CNMC informed consent
template
• Release of private information for research without patient’s authorization is a violation [exceptions described ahead]
![Page 16: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/16.jpg)
Research NOT Covered by HIPPA
Only uses de-identified data:
“. . .health information that does not identify an individual and with respect to which there is no reasonable basis to believe that the information can be used to identify an individual is not individually identifiable health information.”
![Page 17: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/17.jpg)
Research Covered by HIPPA
• Uses individually identifiable health information
• Involves human beings, living or dead
• Doesn’t matter if it is or is not supported by the federal government or regulated by the FDA
![Page 18: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/18.jpg)
Options for Access to PHI
• Use only de-identified data• Obtain patient’s written authorization• Obtain HIPAA waiver from IRB • Review data preparatory to research• Decedent research• Use limited data set
– Data Use Agreement– Business Associate Contract (BAC)
![Page 19: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/19.jpg)
HIPAA Authorization
• Subject cannot participate if HIPAA Written Authorization is not signed*
• States what PHI will be disclosed and to whom
• States how long PHI will be kept; how will it be secured
* Research using PHI
![Page 20: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/20.jpg)
Use of De-identified Data
• Not subject to Privacy Rule
• Can include complete dates, 5-digit ZIP codes, geographic information other than street addresses
• Can have re-identification code if not derived from information about the individual
![Page 21: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/21.jpg)
Waiver of HIPAA Authorization
Justification (must satisfy all 3 criteria):
• Use or disclosure of the PHI presents no more than minimal risk to the individual’s privacy
• Research cannot practicably be conducted without a waiver
• Research cannot be practicably conducted without access to and use of PHI
![Page 22: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/22.jpg)
Data and Safety Monitoring
![Page 23: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/23.jpg)
2nd Belmont Ethical Principle
BENIFICENCE
•“Do no harm”• Maximize possible benefits• Minimize possible harms• Benefits outweigh risks
![Page 24: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/24.jpg)
Data and Safety Monitoring Plans
When appropriate (greater than minimal risk research), the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
• Individual investigator/independent M.D.
• Internal monitoring group (study sponsor)
• Independent Data Safety Monitoring Board (DSMB)
![Page 25: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/25.jpg)
Elements of a DSMP
• What events will be monitored?
• How often?
• Who will monitor them?
• To whom will the information from the monitoring be given?
• What are the “stopping rules,” if any?
![Page 26: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/26.jpg)
Unanticipated Problems in Research
![Page 27: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/27.jpg)
2nd Belmont Ethical Principle
BENIFICENCE
•“Do no harm”• Maximize possible benefits• Minimize possible harms• Benefits outweigh risks
![Page 28: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/28.jpg)
UPIRTSOs
Unanticipated Problems Involving Risks To Subjects or Others
Examples:
• Serious Adverse Events (SAEs)• Protocol deviations
– Failure to obtain informed consent/assent– Eligibility criteria not met; subject still enrolled
• Inadvertent disclosure of PHI• Serious and continuing noncompliance
![Page 29: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/29.jpg)
Adverse Events
• Most are not unanticipated problems– Adverse events expected in the context of
known toxicities or side effects of the research procedures
AND/OR– Due to the natural history of the underlying
diseases and conditions
• Some are unanticipated problems
• Unanticipated problems include events that are not adverse events
![Page 30: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/30.jpg)
OPRP Guidance; October 11, 2005
UPIRTSOs and AEs
![Page 31: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/31.jpg)
Serious Adverse Events (SAEs)
• An untoward medical occurrence during research– E.g., Serious side effects due to study drug or
procedure
• Hospitalization and/or prolongation of hospitalization of subject
• Results in the persistent or significant disability or incapacity of subject
• Death of subject
![Page 32: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/32.jpg)
Reporting SAEs - CNMC IRB Policies
Internal Events (those occurring at CNMC)
• Report deaths within 24 hours (concurrent with reports to FDA, Sponsor)
• Report other serious and unexpected events that are possibly, probably and very likely/certainly related < 5 days after learning of the events (concurrent with reports to FDA)
![Page 33: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/33.jpg)
Reporting SAEs (cont.)
Internal Events (cont.)
• If the event at CNMC is serious or if CNMC is the Coordinating Center, report within 5 days, regardless of its relationship to study intervention
External AEs (those occurring outside CNMC)
• Report events that are serious, unexpected and related within 30 days of learning of them
![Page 34: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/34.jpg)
Protocol Deviation
A one-time, unintentional action or process that departs from the IRB-approved study protocol, involves one incident, and is identified after the event occurs.
![Page 35: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/35.jpg)
Significant deviation:
• directly or potentially disrupts the study progress, such that the study design and results would be compromised
or
• compromises the safety and welfare of study participants
![Page 36: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/36.jpg)
Example 1: Informed Consent Irregularities
• MINOR Deviation: Subject/Parent did not receive a copy of the signed consent form. Upon discovery, a copy is given to the subject at the next visit, or mailed if the subject has since completed the study.
• SIGNIFICANT Deviation: Subject was enrolled without subject/parent signing an informed consent form. Upon discovery, the subject should immediately be consented.
![Page 37: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/37.jpg)
Example 2: Subject Enrolled Did Not Meet Eligibility Criteria
• MINOR Deviation: Subject enrolled was 2 months younger than the lower age limit requirement. Principal Investigator is able to provide rationale for subject admittance and ensure subject safety and study integrity.
• SIGNIFICANT Deviation: A low-birth weight infant was enrolled into a treatment trial for normal weight infants and low weight infants are at higher risk for an adverse event.
![Page 38: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/38.jpg)
Reporting Protocol Deviations
All protocol deviations must be documented on the appropriate form.
Significant deviations must be submitted to the IRB within 10 business days of being identified.
Minor deviations should be filed in the investigator’s study records and submitted to the IRB at continuing review.
![Page 39: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/39.jpg)
Informed Consent and Assent
![Page 40: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/40.jpg)
1st Belmont Ethical Principle
RESPECT FOR PERSONS• Treat individuals as autonomous
agents• Right to know• Right to choose• Right to privacy and confidentiality• Right to withdraw
• Additional protections for persons with reduced autonomy
![Page 41: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/41.jpg)
Regulatory Requirements – Basic Elements of IC
• State that the activity is research
• Describe purpose and duration of study
• Describe procedures
• Identify experimental procedures
• Identify risks
• Identify benefits
• Disclose any alternatives to participation
![Page 42: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/42.jpg)
Basic Elements of IC (cont.)
• Describe the extent of confidentiality
• Explain any available compensation and medical treatment for injury
• State whom to contact about study questions
• State whom to contact about subjects’ rights
• State whom to contact in the event of an injury
• State that participation is voluntary; right to refuse or withdraw
![Page 43: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/43.jpg)
Waiver of Informed Consent/Assent
• Research poses no more than minimal riskDefinition: The probability and magnitude of harm or discomfort anticipated in the proposed research are not greater, in and of themselves, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests [in a healthy person]
![Page 44: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/44.jpg)
Waiver of Informed Consent/Assent (cont.)
• Subjects’ rights and welfare are not adversely affected by waiver
• Research could not be practicably conducted without waiver
• Subjects will be provided with pertinent information after participation, if applicable
CRF 46.102(i)
![Page 45: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/45.jpg)
Documentation of Informed Consent/Assent
• Consent/Assent forms must be approved by IRB; must have approval stamp and expiration dates
• Forms must be signed and dated by subject or subject’s legally authorized representative (LAR)
• Pediatric research: Minor increase over minimal risk, no direct benefit requires signatures of both parents
![Page 46: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/46.jpg)
Pediatric Risk Categories
• Not greater than minimal risk
• More than minimal risk with the prospect of direct benefit to the child
• Minor increase over minimal risk with no prospect of direct benefit
• Not otherwise approvable, but with potential to understand, prevent or alleviate a serious problem
![Page 47: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/47.jpg)
Documentation of IC (cont.)
• Person obtaining consent must sign and date forms after the subject/LAR
• Copy is given to subject/LAR
• Re-consent required when subject reaches age of majority (age 18) and when substantive changes are made
![Page 48: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/48.jpg)
Waiver of Documentation of Informed Consent
• Consent form is the only record linking subject to data and breach of confidentiality is major risk
OR• Activity involves no more than minimal risk
and involves no procedures for which consent is normally required (surveys, blood draws)
HOWEVER, documentation should be provided to subjects who request it
![Page 49: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/49.jpg)
Emergency Use Exemption
Involves use of an investigational agent outside the clinical trial setting
• 2 FDA criteria
– Life-threatening situation; no standard acceptable treatment available
– Insufficient time to convene quorum for full-board IRB approval
• AKA “Compassionate Use”
![Page 50: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/50.jpg)
Emergency Use (cont.)
• Requires Sponsor approval
• Requires consult with independent physician
• Patient unable to participate in clinical trial
• Notify IRB prior to test article’s use if possible
• IRB must be notified within 5 days of use
![Page 51: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/51.jpg)
Collaborative Research at Multiple Sites
![Page 52: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/52.jpg)
Which IRB Has Oversite?
• CNMC (local) IRB
• Lead site IRB
• Central IRB (e.g., pediatric oncology)
• External IRB -- Western IRB: industry-sponsored
protocols
![Page 53: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/53.jpg)
Determining the IRB of Record
• Cooperative Agreements between CNMC and collaborating institutions
• Protocol submitted to two or more collaborating sites
• IRB Chairs discuss where consent is obtained, where primary risks can occur
• IRB Chairs determine which IRB(s) will have approval and oversight responsibility
• PI provides documentation of initial and continuing approvals to secondary IRB
![Page 54: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/54.jpg)
Continuing Review
Mandatory under federal regulations• Approvals period < 365 days
• Reminders sent to investigators 90 days prior to study expiration
• Failure to submit progress report in time to permit re-approval = non-compliance
• Expired approval = Study closed (Must submit new protocol)
![Page 55: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/55.jpg)
Protocol Closure
• Protocol is closed to further research activities including data analysis– Exception: Industry sponsored studies
• Submit Cont. Review/Closure form to IRB – Total N– Adverse events– Outcomes; publications
• Failure to close = expired protocol and possible non-compliance
![Page 56: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/56.jpg)
Intranet Resources
http://intranet.cnmc.org/RESEARCH/DEFAULT.ASPX
• IRB submission forms• HRPP policies and procedures• CITI training information• Educational presentations• HRPP newsletter• Staff contact information
![Page 57: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/57.jpg)
![Page 59: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/59.jpg)
OPHS Staff
Birdena Samuel (Manager) (301) 565-8488
Roslyn Edson (IRB 01) (301) 565-8489
Loretta Polite (IRB 04) (301) 565-8541
Jan Martinez (Continuing Reviews) (301) 565-8542
Gloria Lawrence (Central IRB) (301) 565-8479
Maryann Rossi (301) 565-8485 (Accreditation and Education Manager)
![Page 60: Advanced Topics in the Submission of Research Protocols to the Institutional Review Board (IRB) and the Office for the Protection of Human Subjects (OPHS)](https://reader035.vdocument.in/reader035/viewer/2022062717/56649e185503460f94b05346/html5/thumbnails/60.jpg)
Paper Submissions
Send submission materials via Inter-departmental Mail to:
IRB/OPHS
801 Roeder Road Suite 500
Silver Spring